Barbara   Burtness , MD

Barbara Burtness , MD

Yale Cancer Center/Smilow Cancer Hospital

Professor of Medicine (Medical Oncology); Chief Translational Research Officer, Yale Cancer Center; Chief, Head and Neck Cancers/Sarcoma; Co-Leader, Developmental Therapeutics, Yale Cancer Center

Expertise: Head And Neck CancerSarcomaMedical Oncology

Barbara Burtness, MD is a Professor of Medicine (Medical Oncology) at the Yale School of Medicine, Chief Translational Research Officer, and Associate Cancer Center Director for Translational Research at the Yale Cancer Center. She serves as Co-Leader of the Developmental Therapeutics Program, Division Chief for Head and Neck/Sarcoma Oncology, and Director of the Yale Head and Neck Specialized Program of Research Excellence. Dr. Burtness is internationally recognized for her research in head and neck cancer. She chairs the ECOG-ACRIN Cooperative Group Head and Neck Cancer Therapeutics Committee and the ECOG-ACRIN Task Force for the Advanc, and leads national and international trials of targeted therapy in head and neck cancer. Her laboratory studies synthetic lethal therapeutic strategies in head and neck cancer and the targeting of aurora kinase A to overcome adaptive resistance to EGFR inhibition and - in lung cancer- to direct KRAS inhibition. 

No Clipping

No Research/Citations

Researchers develop a new way to classify HPV-associated head and neck cancers

Human papillomavirus (HPV) has been linked to a significant increase in cancers of the throat and tonsils over the past few decades; this is projected to become the most common form of head and neck cancer by 2030. But a major limitation to reducing treatment intensity is the inability to correctly identify the patients whose HPV-related cancers will be the most responsive to treatment.
31-Jul-2023 03:05:36 PM EDT

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video